

Passion for Innovation.
Compassion for Patients.™



Daiichi-Sankyo



Post-Doctoral Pharmaceutical Industry Fellowships



ST. JOHN'S
UNIVERSITY

Today, we innovate by creating new medicines, as well as new methods of drug discovery and delivery. We strive to constantly develop, deepen and broaden our pipeline to address unmet medical needs.



Contents

Welcome Letter.....	3
About Daiichi Sankyo, Inc.	4
Cancer Enterprise	6
About the Fellowships	9
Fellowship Program History.....	9
Quantitative Clinical Pharmacology Fellowship Program Structure	10
Clinical Development - Oncology Fellowship Program Structure	11
Current Fellow Perspectives	12
The Fellowship Team.....	14
Past Fellows.....	16
2019–2021 Preceptor Testimonials	17
St. John’s University Overview	18
Benefits of the Fellowship.....	18
St. John’s University Component	19
Application Process & Eligibility Requirements.....	20

Welcome

Thank you for your interest in the St. John’s University / Daiichi Sankyo, Inc. Post-Doctoral Fellowship Program. Daiichi Sankyo, Inc. and St. John’s University strive to increase the visibility of the pharmacy profession and its role in shaping the pharmaceutical industry.

During the course of this Fellowship, Fellows become involved in both pharmaceutical industry and academia by being immersed in an international company through projects and as members of multi-disciplinary teams. Fellows also complete educational and research activities at St. John’s University. Daiichi Sankyo is a(n):

- Innovative company that has a plethora of novel products in its pipeline
- International industry leader
- Dedicated entity in promoting health and well-being across multiple disease states

We wish you the best of luck, welcome your interest, and urge you to consider applying to these Fellowship Programs.

Daiichi Sankyo, Inc. is the U.S. subsidiary of Daiichi Sankyo Co., Ltd., a global pharmaceutical company.

Daiichi Sankyo has a 100-year history of innovation and discovery, with a primary focus on bringing forth novel therapies in oncology and additional focus on new horizon areas.

Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical therapies to improve standards of care and address diversified, unmet medical needs of people globally by leveraging our world-class science and technology. With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 15,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to a strong portfolio of medicines for cardiovascular diseases, under the Group's 2025 Vision to become a "Global Pharma Innovator with Competitive Advantage in Oncology," Daiichi Sankyo is primarily focused on providing novel therapies in oncology, as well as other research areas centered around rare diseases and immune disorders. For more information, please visit www.daiichisankyo.com.

A Rich Legacy



Daiichi Sankyo, Inc. is a member of the Daiichi Sankyo Group and is focused on the development of oncology therapies and specialty medicines. Daiichi Sankyo, Inc. medicines approved in the U.S. include therapies for hypertension, dyslipidemia, diabetes, thrombosis, stroke risk reduction, acute coronary syndrome, IV iron therapy, metastatic melanoma and tenosynovial giant cell tumors.



HEADQUARTERS

★ **U.S.** Daiichi Sankyo, Inc.
211 Mt. Airy Road,
Basking Ridge, NJ 07920
Phone: +1 908 992 6400

🌐 **Global** Daiichi Sankyo Co., Ltd.
3-5-1, Nihonbashi Honcho,
Chuo-ku, Tokyo, 103-8426 Japan


REVENUE FY18

🌐 Global	★ U.S.
\$8,382 million	\$1.389 billion*

Values & Commitments



Daiichi-Sankyo



*SOC (Standard of Care): Universally applied best treatment practice in today's medical science

Looking Ahead

Daiichi Sankyo Co., Ltd. is striving to satisfy unmet medical needs as a developer of new drugs, including vaccines, generic and OTC drugs, that meet a variety of medical needs.

As a leader in the healthcare industry, we recognize that we not only have a responsibility to provide the medicines that are indispensable to healthcare systems around the world, but we must also fund the research and development that ensures the availability of tomorrow's innovative medicines.

Our pipeline is rich with potential medications for oncology including treatments for cancers such as acute myeloid leukemia (AML), solid tumors and breast cancer.



Daiichi Sankyo Cancer Enterprise

The mission of Daiichi Sankyo Cancer Enterprise is to leverage our world-class, innovative science and push beyond traditional thinking in order to create meaningful treatments for patients with cancer. We are dedicated to transforming science into value for patients, and this sense of obligation informs everything we do.



World Class Science Organization

The Daiichi Sankyo Cancer Enterprise is committed to becoming a leading world-class science organization. Our team's exceptional scientific attitude results in outstanding medicinal chemistry, antibody engineering and discovery biology.

Dynamic and Sustainable R&D Organization

Our portfolio is powered by our research engines including two laboratories for biologic/immunology and small molecules in Japan, and Plexikon Inc., our small molecule structure-guided R&D center in Berkeley, CA.

7 New Molecular Entities by 2025

Anchored by three pillars including our investigational Antibody Drug Conjugate Franchise, Acute Myeloid Leukemia Franchise and Breakthrough Science Franchise, we aim to deliver seven distinct new molecular entities—one of which was just approved in August, 2019—over eight years during 2018 to 2025.

Enhanced Capabilities Through Collaboration

To complement and expand our premier cadre of internal scientists, we are collaborating with leading academic and business partners to leverage cutting-edge science in new treatment modalities, disease biology, diagnostics and pipeline prioritization.





About the Fellowships

The St. John's University / Daiichi Sankyo Fellowship Program is unique in that Fellows can rotate through various departments, depending on their interests.

Moreover, the individualized attention given to Fellows fosters their ability to become influential leaders in the pharmaceutical industry. The St. John's University / Daiichi Sankyo Fellowship Program was created in 2011 to help accelerate the learning and stimulate the professional development of Fellows in the pharmaceutical industry. Fellows collaborate with and are integral members of multi-disciplinary teams.

The Program provides a broad understanding of the global drug development process and assists each Fellow's understanding of the key roles that Quantitative Clinical Pharmacology and Clinical Development have in the drug development process, including the opportunity to gain "hands-on" experience concerning the requirements to identify, develop and market new medications. Additionally, the Fellow will enhance their knowledge through educational and research activities at St. John's University, College of Pharmacy and Health Sciences.

Fellowship Program History

Daiichi Sankyo is dedicated to providing its Fellows the most rewarding professional experience possible.

Every year the Fellowship Preceptors gauge where the company will have the most exciting and challenging work projects. The Fellowship Program is altered according to Daiichi Sankyo, Inc.'s business needs for the year. Past Fellows have focused in Regulatory Affairs, Clinical Development, and Clinical Safety, and this year we are proud to offer Fellowship positions in Quantitative Clinical Pharmacology and Clinical Development, focusing on the field of oncology. This type of flexibility within the St. John's University / Daiichi Sankyo Fellowship Program creates an opportunity for diversity and provides a unique and rewarding experience to each Fellow every year.

Quantitative Clinical Pharmacology - Oncology Fellowship Program Structure

The Fellowship is designed to focus in the area of Quantitative Clinical Pharmacology-Oncology. Below is a summary of activities and outcomes by program year.

FIRST YEAR

- Develop and implement innovative early clinical development strategies from first-in-man through pharmacological/ biomarker proof of concept (Phase 1b/Phase 2a) across all therapeutic areas and geographic regions
- Act as a study scientific lead on Clinical Pharmacology studies such as special population studies (renal and hepatic insufficiency populations), drug-drug interaction studies, food effect studies and ADME studies
- Develop and implement clinical pharmacology programs that support product development, registration, differentiation and personalization
- Institute state-of-the-art PK/PD modeling and simulation to optimize study design and interpretation, predict clinical safety/efficacy, and support decision making and product development
- Utilize quantitative imaging, including functional and molecular imaging, to fulfill our mission

SECOND YEAR

- Continue the work in year one with more advanced projects
- AND/OR -
- Rotate (3-6 months) through various departments at Daiichi Sankyo and externally, dependent on Fellow's level of interest and/or projects with a high priority level within the organization.

Rotations may include but not be limited to:

- Clinical Development
- Clinical Safety and Pharmacovigilance
- Regulatory Affairs
- Pharmacoepidemiology
- Project Management
- FDA

Clinical Development - Oncology

Fellowship Program Structure

This Fellowship is designed to focus in the area of Clinical Development - Oncology. Below is a summary of activities and outcomes by program year.

FIRST YEAR

- Spend at least one full year within the Clinical Development department
- Learn strategies and processes for clinical trial start-up, execution and completion
- Acquire working knowledge of protocol development, case report form design, trial governance and management, medical monitoring, subject recruitment and retention, monitoring of investigational sites, data management, statistical analysis and clinical study report preparation
- Learn strategies for effective oversight and management of contract research organizations and other vendors, thereby ensuring that trials are conducted in accordance with Daiichi Sankyo Pharma Development Standard Operating Procedures (SOPs) and Good Clinical Practice (GCP) standards as well as federal and other national regulations
- Support the clinical operations team with trial implementation and management (e.g., planning investigator meetings, managing drug supply, management of investigational sites) to ensure high quality deliverables
- Present progress reports from ongoing clinical trials
- Participate on a cross-functional clinical trial team to assist with execution of the trial
- Attend national scientific conferences, medical meetings and key opinion leader meetings
- Prepare and present poster/abstracts/scientific papers
- Collaborate cross-functionally with global colleagues and scientists, representing diverse backgrounds, knowledge and expertise on a variety of issues and topics

SECOND YEAR

- Continue the work in year one with more advanced projects
- AND/OR -**
- Rotate (3-6 months) through various departments at Daiichi Sankyo and externally, dependent on Fellow's level of interest and/or projects with a high priority level within the organization.

Rotations may include but not be limited to:

- Quantitative Clinical Pharmacology
- Clinical Safety and Pharmacovigilance
- Regulatory Affairs
- Pharmacoepidemiology
- Project Management
- FDA

“The St. John’s / Daiichi Sankyo Fellowship...”



...is full of opportunities to gain real-world and leadership experience.

As a fellow, I have been involved in numerous important projects within the field of Oncology that have helped me develop my skills within the industry. Also, individual preceptors are dedicated in providing you with experiences that will further your personal and professional growth. Fellows will have an opportunity to interact with different cross-functional teams and explore other areas of interest during their second year. My experience at Daiichi Sankyo has been tremendously rewarding and I look forward to the remainder of this journey.”

Ben Kim, Pharm.D.

University of Michigan
Second-Year Clinical Safety Fellow
2018–2020



...offers a broad range of experiences within a functional area which would not be available in most other companies.

Daiichi Sankyo is the quintessential mid-size pharmaceutical company which offers an assortment of unique benefits. Fellows have the range to rotate and/or assist with projects in every level within a functional area and have access to a large enough drug pipeline to learn from multiple therapeutic areas. Each fellow has their own individualized experience that is aligned with their interests and they have many opportunities to make their impression on industry leaders. The program also includes an academic component where the Fellow can gain teaching experience. I believe without a doubt in my mind that the experiences I gain as a Fellow will prepare me for successful career in industry.”

Mark Lee, Pharm.D., M.S.

University of Maryland
Second-Year Quantitative Clinical Pharmacology Fellow
2018–2020



...allows fellows to explore a broad range of experiences that will help them to develop their skills within the pharmaceutical industry.

As a fellow, you get the opportunity to work with many different individuals across different functional areas, and get a front seat view of how each person's role on the team creates a successful program. Individual preceptors are extremely receptive to the needs of a fellow, and work with you to determine the best way for you to learn about and succeed in your role. Additionally, the collaboration with the St. John's academic component provides the fellow with invaluable teaching and research experience, should they choose to follow that path. I believe that this fellowship program will equip fellows with all the tools needed to be competitive in their future industry career."

Alvileen Diggs, Pharm.D.

University of Maryland
First-Year Clinical Safety Fellow
2019-2021



...exposes fellows to a breadth of experiences they may not have had outside of a fellowship program.

These opportunities equip fellows with the necessary skills to jumpstart a career in the pharmaceutical industry. At Daiichi Sankyo, teams are very eager to teach you, and encourage you to participate in a variety of cross-functional meetings and projects. All the experiences as a fellow will be geared towards ensuring that you are a competitive candidate in the industry. Additionally, having an academic portion with St. John's University allows fellows to fine tune their communication skills, through teaching and research opportunities."

Pranav Patel, Pharm.D.

Rutgers University
First-Year Regulatory Affairs Fellow
2019-2021



THE FELLOWSHIP TEAM



PAST FELLOWS



**Hoang Pham,
Pharm.D.**

- Manager, Clinical Safety and Pharmacovigilance
- Daiichi Sankyo, Inc.
- Fellow 2017-2019



**Elan Lutinger,
Pharm.D., M.B.A.**

- Specialist CAR-T
- Johnson & Johnson
- Fellow 2014-2016



**Allison Allen,
Pharm.D.**

- Manager, Regulatory Affairs
- CSL Behring
- Fellow 2017-2019



**Derek E. Mires,
Pharm.D.**

- Associate Director, Global Oncology R&D
- Daiichi Sankyo, Inc.
- Fellow 2013-2015



**Neil Dhopeswarkar,
Pharm.D.**

- Ph.D. Candidate in Pharmacoepidemiology
- University of Pennsylvania
- Fellow 2016-2018



**Mike DeMarco,
Pharm.D., M.B.A.**

- Engagement Manager
- PwC
- Fellow 2012-2014



**Michele Vigliotti,
Pharm.D.**

- Manager, Clinical Development
- Pfizer
- Fellow 2016-2018




**Neda Aghajani Memar,
Pharm.D.**

- Associate Director, Regulatory Affairs
- Ovid Therapeutics
- Inaugural Fellow 2011-2013



**Nicole Liaw,
Pharm.D.**

- Senior Manager, Regulatory Affairs Strategy
- Celgene
- Fellow 2015-2017



2019-2021 PRECEPTOR TESTIMONIALS



“The mission of Daiichi Sankyo’s Cancer Enterprise is to lead in science and transform evidence into value for cancer patients in need. The fellowship program in Quantitative Clinical Pharmacology (QCP) will provide a unique opportunity to integrate clinical drug exposure, efficacy, safety and biomarker data using novel clinical study designs and analyses. The fellow will be part of global drug development teams, will contribute to the clinical profiling of drugs and help optimize dose and dosing regimen selection. By the end of the fellowship in QCP, the fellow will have a good understanding of the drug development process and will be able to design and interpret the results of clinical pharmacology studies in healthy volunteers and special patient populations.”

**Quantitative Clinical Pharmacology Preceptor:
Malaz Abutarif, BSc (Pharmacy), PhD, MBA**


Executive Director, Quantitative Clinical Pharmacology



“It is very exciting to work on the cutting edge of cancer research in a company with such an extraordinary oncology clinical development pipeline. This fellowship program will provide a very rich experience in Clinical Development from early phase to late phase. Fellows will actively participate in multi-disciplinary teams, gain a strong foundation in all aspects of drug development, and have opportunities to present their work.”

Clinical Development Preceptor: Sabeen Mekan

Senior Director, Global Oncology R&D



St. John's University

COLLEGE OF PHARMACY AND HEALTH SCIENCES

St. John's University's primary campus is located on a residential 105-acre campus in Queens, New York and was founded in 1870 by the Congregation of Mission (Vincentian) Community. Recognized for its outstanding academic programs, rich student life, vibrant diversity and Big East vitality, the university boasts a population of over 20,000 students and 140,000 alumni across a number of campuses both in the United States and internationally.

The nationally recognized College of Pharmacy and Health Sciences prepares students for rewarding careers as practitioners, researchers and leaders in health care institutions, government and industry. Founded in 1929, the College offers numerous healthcare-related programs at the undergraduate and graduate levels including the Doctor of Pharmacy degree, Master of Science degrees in Pharmacy Administration and Public Health, and the Doctor of Philosophy in Pharmaceutical Sciences degree.

St. John's College of Pharmacy and Health Sciences is committed to shaping compassionate health care professionals to serve humanity through excellence in health care and biomedical research. Faculty, students and alumni of the College are actively involved in basic science as well as clinical research, and provide effective pharmaceutical care to a diverse patient population. The College continually works in partnership with numerous healthcare organizations throughout the New York metropolitan area to ensure the promotion, practice and delivery of the highest-quality health care services and research. Building on a dedication to greatness, its metropolitan location and its strategic alliances with leading healthcare institutions, the empowers effective leaders, good citizens and moral and ethical individuals. With its enhanced commitment to global education St. John's University also provides students with the opportunity to gain experience from an ever increasing global perspective.

Benefits of the Fellowship

Fellows are full time employees of St. John's University. In addition to being an excellent training and learning opportunity, the Fellowship provides a competitive stipend and benefits package, including individual comprehensive health insurance through St. John's University.

Upon successful completion of the Fellowship Program, a certificate of completion will be awarded by St. John's University College of Pharmacy and Health Sciences and Daiichi Sankyo, Inc.

St. John's University Component

Each Fellow will have opportunities at the University to participate in activities to promote professional development including:

- Formal and informal educational opportunities
- Completion of a formal teaching excellence program
- Active participation in the College's Fellows/residents seminar series
- Tuition remittance for graduate degrees
- Collaborative research projects with St. John's faculty
- Enrollment in Graduate degree programs available at the University to further his or her educational development (Master's or PhD degrees)
- On-campus teaching opportunities within the Doctor of Pharmacy Program
- Completion of an individual research project
- Precepting Pharm.D. students



ST. JOHN'S
UNIVERSITY



Application Process & Eligibility Requirements

To be eligible, candidates must be graduates of an Accreditation Council for Pharmacy Education (ACPE) accredited Doctor of Pharmacy Program before July 1 of the Fellowship term and have a strong interest in a career in the pharmaceutical industry. Participation in the American Society of Health-Systems Pharmacist (ASHP) Midyear Clinical Meeting Personnel Placement Service (PPS) is strongly encouraged.

Interested Candidates Should Send:

REQUIRED ITEM

- Curriculum Vitae
- Letter of intent
- College transcript
- Three letters of recommendation

DEADLINE

December 16, 2019
December 16, 2019
December 16, 2019
December 16, 2019

Please send all correspondence to:

MAIL HARD COPIES TO:

Joseph M. Brocavich, Pharm.D.
Senior Associate Dean for Pharmacy
Associate Clinical Professor
College of Pharmacy and Health Sciences
St. John's University
8000 Utopia Parkway
Queens, New York 11439

MAIL ELECTRONIC COPIES TO:

Send emails to both:

- Joseph M. Brocavich, Pharm.D.
brocavij@stjohns.edu
- Daiichi Sankyo
DSIFellowship@dsi.com

More Information

For any additional information or questions:

ST. JOHN'S UNIVERSITY

Visit: www.stjohns.edu/academics/schools-and-colleges/college-pharmacy-and-health-sciences/residency-and-fellowship-programs

DAIICHI SANKYO, INC.

Email: DSIFellowship@dsi.com





ST. JOHN'S
UNIVERSITY



Passion for Innovation.
Compassion for Patients.™

©2019 Daiichi Sankyo, Inc.